Tecogalan sodium

Drug Profile

Tecogalan sodium

Alternative Names: DS 4152; SP PG; SP PG LM

Latest Information Update: 03 Nov 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Daiichi Pharmaceutical; National Cancer Institute (USA)
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections; Kaposi's sarcoma; Solid tumours

Most Recent Events

  • 03 Nov 1999 Discontinued-I for Kaposi's sarcoma in European Union (Unknown route)
  • 01 Oct 1998 Discontinued-I for Solid tumours in European Union (Unknown route)
  • 01 Oct 1998 Discontinued-Preclinical for HIV infections treatment in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top